Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway
Women's Issues in Multiple Sclerosis.
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns.
Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction.
Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators.
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Mechanisms of action for treatments in multiple sclerosis: Does a heterogeneous disease demand a multi-targeted therapeutic approach?
BRIEF: Teva files for Copaxone-Laquinimod patent
Defining the Role of Physiotherapy in Palliative Care in Multiple Sclerosis.
Perk Ablation Ameliorates Myelination in S63del-Charcot-Marie-Tooth 1B Neuropathy.
Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis.
An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination.
Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients.
New data reinforce efficacy of TECFIDERA® (dimethyl fumarate) in MS patients with high disease activity
Factors in Patient Empowerment: A Survey of an Online Patient Research Network.
[Flow cytometry model for the detection of neutralizing antibodies against of IFN-β].
Techniques and technologies for the bioanalysis of Sativex(®), metabolites and related compounds.
Correlation of the patient's reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies.
Rebound Relapses After Ceasing Another Disease-Modifying Treatment in Patients With Multiple Sclerosis: Are There Lessons to Be Learned?
PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
Three-Month Test-Retest Reliability of Center of Pressure Motion During Standing Balance in Individuals with Multiple Sclerosis.
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
Reassessing the risk of natalizumab-associated PML.
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.

Pages